Cargando…

Pre‐dispensing of antivirals to high‐risk individuals in an influenza pandemic

Please cite this paper as: Goldstein et al. (2010) Pre‐dispensing of antivirals to high‐risk individuals in an influenza pandemic. Influenza and other Respiratory Viruses 4(2), 101‐112. We consider the net benefits of pre‐dispensing antivirals to high‐risk individuals during an influenza pandemic, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldstein, Edward, Miller, Joel C., O’Hagan, Justin J., Lipsitch, Marc
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3075926/
https://www.ncbi.nlm.nih.gov/pubmed/20167050
http://dx.doi.org/10.1111/j.1750-2659.2009.00128.x
_version_ 1782201798625329152
author Goldstein, Edward
Miller, Joel C.
O’Hagan, Justin J.
Lipsitch, Marc
author_facet Goldstein, Edward
Miller, Joel C.
O’Hagan, Justin J.
Lipsitch, Marc
author_sort Goldstein, Edward
collection PubMed
description Please cite this paper as: Goldstein et al. (2010) Pre‐dispensing of antivirals to high‐risk individuals in an influenza pandemic. Influenza and other Respiratory Viruses 4(2), 101‐112. We consider the net benefits of pre‐dispensing antivirals to high‐risk individuals during an influenza pandemic, where the measure of the benefit is the number of severe outcomes (such as deaths or hospitalizations) prevented by antivirals in the whole population. One potential benefit of pre‐dispensing is that individuals to whom antivirals have been pre‐dispensed may be able to initiate treatment earlier than if they had to wait to obtain and fill a prescription, reducing their risk of progression to severe disease. If this benefit exceeds the side effects of misuse for the category of individuals to whom antivirals were pre‐dispensed, and if antiviral supply exceeds overall population demand (which appears relevant for several countries including US in the 2009 H1N1 pandemic), pre‐dispensing a quantity of antivirals not exceeding the difference between supply and demand is always beneficial. In this study, we consider the net benefits of pre‐dispensing antivirals under various scenarios, including demand exceeding supply, and derive mathematical conditions under which antiviral pre‐dispensing is advantageous on balance. For individuals whose relative risk of severe outcome is high enough, such as immunosuppressed individuals (particularly children) and possibly individuals with neurological disorders, pre‐dispensing is always beneficial at a given level of antiviral stockpile with modest assumptions on the relative benefit of early treatment by a pre‐dispensed course, regardless of the overall population demand for antivirals during the course of an epidemic. Making additional assumptions on either the overall population demand for antivirals (which appear relevant for the 2009 H1N1 pandemic) or on the relative benefit of pre‐dispensing would make pre‐dispensing net beneficial with inclusion of a larger number of persons such as pregnant women and morbidly obese adults.
format Text
id pubmed-3075926
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-30759262011-04-13 Pre‐dispensing of antivirals to high‐risk individuals in an influenza pandemic Goldstein, Edward Miller, Joel C. O’Hagan, Justin J. Lipsitch, Marc Influenza Other Respir Viruses Review Article Please cite this paper as: Goldstein et al. (2010) Pre‐dispensing of antivirals to high‐risk individuals in an influenza pandemic. Influenza and other Respiratory Viruses 4(2), 101‐112. We consider the net benefits of pre‐dispensing antivirals to high‐risk individuals during an influenza pandemic, where the measure of the benefit is the number of severe outcomes (such as deaths or hospitalizations) prevented by antivirals in the whole population. One potential benefit of pre‐dispensing is that individuals to whom antivirals have been pre‐dispensed may be able to initiate treatment earlier than if they had to wait to obtain and fill a prescription, reducing their risk of progression to severe disease. If this benefit exceeds the side effects of misuse for the category of individuals to whom antivirals were pre‐dispensed, and if antiviral supply exceeds overall population demand (which appears relevant for several countries including US in the 2009 H1N1 pandemic), pre‐dispensing a quantity of antivirals not exceeding the difference between supply and demand is always beneficial. In this study, we consider the net benefits of pre‐dispensing antivirals under various scenarios, including demand exceeding supply, and derive mathematical conditions under which antiviral pre‐dispensing is advantageous on balance. For individuals whose relative risk of severe outcome is high enough, such as immunosuppressed individuals (particularly children) and possibly individuals with neurological disorders, pre‐dispensing is always beneficial at a given level of antiviral stockpile with modest assumptions on the relative benefit of early treatment by a pre‐dispensed course, regardless of the overall population demand for antivirals during the course of an epidemic. Making additional assumptions on either the overall population demand for antivirals (which appear relevant for the 2009 H1N1 pandemic) or on the relative benefit of pre‐dispensing would make pre‐dispensing net beneficial with inclusion of a larger number of persons such as pregnant women and morbidly obese adults. Blackwell Publishing Ltd 2010-02-09 2010-03 /pmc/articles/PMC3075926/ /pubmed/20167050 http://dx.doi.org/10.1111/j.1750-2659.2009.00128.x Text en © 2010 Blackwell Publishing Ltd
spellingShingle Review Article
Goldstein, Edward
Miller, Joel C.
O’Hagan, Justin J.
Lipsitch, Marc
Pre‐dispensing of antivirals to high‐risk individuals in an influenza pandemic
title Pre‐dispensing of antivirals to high‐risk individuals in an influenza pandemic
title_full Pre‐dispensing of antivirals to high‐risk individuals in an influenza pandemic
title_fullStr Pre‐dispensing of antivirals to high‐risk individuals in an influenza pandemic
title_full_unstemmed Pre‐dispensing of antivirals to high‐risk individuals in an influenza pandemic
title_short Pre‐dispensing of antivirals to high‐risk individuals in an influenza pandemic
title_sort pre‐dispensing of antivirals to high‐risk individuals in an influenza pandemic
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3075926/
https://www.ncbi.nlm.nih.gov/pubmed/20167050
http://dx.doi.org/10.1111/j.1750-2659.2009.00128.x
work_keys_str_mv AT goldsteinedward predispensingofantiviralstohighriskindividualsinaninfluenzapandemic
AT millerjoelc predispensingofantiviralstohighriskindividualsinaninfluenzapandemic
AT ohaganjustinj predispensingofantiviralstohighriskindividualsinaninfluenzapandemic
AT lipsitchmarc predispensingofantiviralstohighriskindividualsinaninfluenzapandemic